Catalent Inc (NYSE:CTLT) – Equities research analysts at Jefferies Financial Group increased their FY2019 earnings estimates for Catalent in a report released on Wednesday, May 8th. Jefferies Financial Group analyst D. Windley now expects that the company will post earnings per share of $1.74 for the year, up from their previous forecast of $1.71. Jefferies Financial Group has a “Hold” rating and a $50.00 price target on the stock. Jefferies Financial Group also issued estimates for Catalent’s Q1 2020 earnings at $0.19 EPS, Q4 2020 earnings at $0.74 EPS and FY2020 earnings at $1.82 EPS.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.07. The company had revenue of $617.50 million during the quarter, compared to the consensus estimate of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. Catalent’s revenue was down 1.7% on a year-over-year basis. During the same period last year, the business posted $0.41 earnings per share.
Shares of CTLT opened at $43.99 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.18 and a quick ratio of 1.63. The company has a market cap of $6.52 billion, a P/E ratio of 27.67, a price-to-earnings-growth ratio of 2.38 and a beta of 1.70. Catalent has a 12 month low of $29.23 and a 12 month high of $47.04.
In other news, Director Gregory T. Lucier bought 2,000 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was acquired at an average cost of $45.08 per share, with a total value of $90,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Aristippos Gennadios sold 3,392 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $42.18, for a total value of $143,074.56. The disclosure for this sale can be found here. Insiders sold 54,326 shares of company stock valued at $2,303,676 over the last three months. Company insiders own 1.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in Catalent by 36.0% during the third quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock valued at $4,997,000 after buying an additional 29,008 shares during the period. JPMorgan Chase & Co. boosted its stake in Catalent by 29.5% during the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after buying an additional 1,819,020 shares during the period. First Bank & Trust boosted its stake in Catalent by 13.9% during the fourth quarter. First Bank & Trust now owns 4,600 shares of the company’s stock valued at $143,000 after buying an additional 563 shares during the period. Blueshift Asset Management LLC bought a new stake in Catalent during the fourth quarter valued at $815,000. Finally, Jennison Associates LLC boosted its stake in Catalent by 269.7% during the fourth quarter. Jennison Associates LLC now owns 1,144,566 shares of the company’s stock valued at $35,688,000 after buying an additional 834,939 shares during the period. 96.85% of the stock is owned by hedge funds and other institutional investors.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Stock Symbol
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.